Drifting Toward AD—Epigenetic Changes Linked to Disease
You can’t do anything about the genome you were born with, but you may be able to change your epigenome...
6389 RESULTS
Sort By:
You can’t do anything about the genome you were born with, but you may be able to change your epigenome...
There is a possibility that the rate of ventricular enlargement over six months could be a useful marker for AD progression...
Two papers in the 19 July Lancet bring both dismay and hope to the ongoing quest for more effective AD treatments...
PBT2, a zinc/copper ligand that may act like an ionophore, shows dramatic effects on cognition in transgenic mouse models of AD...
Presenilins may now have a new claim to fame...
Alternative splicing of messenger RNAs can result in the production of protein isoforms with different functions...
Overproduction seems to be a major problem for neurons...
From yeast to mammals, the realization that calorie restriction (CR) increases lifespan led to the mantra “eat less—live longer”...
New data on an assortment of therapeutic possibilities appear this week...
Paris: Intracellular Traffic and Neurodegenerative Disorders Ipsen Colloquium on Alzheimer’s Disease 2008
The inside of a cell is a very busy place...
Flurizan has floundered in an 18-month Phase 3 clinical trial in patients with mild Alzheimer disease...
There is an inherent dilemma in how best to ensure protection for cognitively vulnerable subjects without impeding research...
One way of catching up on what the ASG is doing to support the nation’s fight against AD is to read the companion story...
In response to rising calls for action, last year, the Alzheimer’s Study Group (ASG) was formed...
No filters selected